Security
Serina Therapeutics, Inc. · SER
SERNYSE_AMERICANCommon stockCurrentCIK 1708599Updated Oct 12, 2026
Name history
AgeX Therapeutics, Inc. · through Apr 1, 2024
SER price & chart
Loading TradingView…
AMEX:SER on TradingView ↗About the company
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ Platform™ (“POZ”) drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an improved efficacy and safety profile of the resulting polymeric drug conjugate. Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for central nervous system (“CNS”) indications, including Parkinson’s disease. Our lead product candidate, SER-252 (POZ-apomorphine), is a POZ conjugate of the dopamine agonist apomorphine being developed for the treatment of advanced Parkinson’s disease. In January 2026, we received clearance of our Investigational New Drug application from the U.S. Food and Drug Administration for SER-252. In February 2026, we enrolled and dosed our first patient in our Phase 1b single-ascending dose (“SAD”) clinical trial for SER-252. For additional information about our business, operations, and financial results, see the documents listed under “Where You Can Find More Information.”
In the news
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates ↗
Recent filings
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Other Events
Items 8.01, 9.01
EFFECT filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
S-1 filing
Show 5 more recent filings
S-8 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 12,413,000Source | 7,435,000Source | 25,814,000Source | 8,941,000Source | 10,708,000Source | 27,299,000Source | 6,731,000Source | 10,856,000Source | 6,951,000Source | 6,724,000Source | 11,965,000Source | 3,241,000Source |
| Property, Plant and Equipment, NetUSD | 580,000Source | 519,000Source | 482,000Source | 588,000Source | 540,000Source | 472,000Source | 484,000Source | 564,000Source | 465,000Source | 501,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 509,000Source | — | — | 541,000Source | — | — | 574,000Source | — | — | 607,000Source | 738,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,620,000Source | 3,185,000Source | 23,024,000Source | 6,041,000Source | 6,064,000Source | 24,526,000Source | 4,267,000Source | 8,706,000Source | 3,056,000Source | 3,672,000Source | 345,000Source | 645,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | 65,000Source | — | — | 57,000Source | 4,000Source |
| Assets, CurrentUSD | 11,497,000Source | 5,423,000Source | 25,030,000Source | 7,991,000Source | 8,917,000Source | 26,474,000Source | 5,754,000Source | 8,937,000Source | 6,080,000Source | 5,676,000Source | 754,000Source | 2,453,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,877,000Source | 2,224,000Source | 2,006,000Source | 1,950,000Source | 2,802,000Source | 1,948,000Source | 1,487,000Source | 166,000Source | 3,024,000Source | 2,004,000Source | 352,000Source | 1,804,000Source |
| Operating Lease, Right-of-Use AssetUSD | 312,000Source | 509,000Source | 277,000Source | 362,000Source | 562,000Source | 328,000Source | 412,000Source | 627,000Source | 377,000Source | 461,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 10,819,000Source | 21,263,000Source | 7,084,000Source | 7,295,000Source | 27,101,000Source | 9,671,000Source | 5,172,000Source | 15,165,000Source | 6,988,000Source | 6,216,000Source | 6,607,000Source | 20,556,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 4,940,000Source | 0Source | 0Source | 4,940,000Source | — | 4,940,000Source | — | — | 4,940,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 3,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | 1,000Source | — | 4,000Source |
| Additional Paid in CapitalUSD | 56,987,000Source | 8,000,000Source | 95,481,000Source | 52,440,000Source | 6,821,000Source | 83,093,000Source | 50,831,000Source | 1,125,000Source | 58,536,000Source | 44,958,000Source | 136,482,000Source | 98,994,000Source |
| Retained Earnings (Accumulated Deficit)USD | -60,164,000Source | -21,775,000Source | -76,754,000Source | -55,579,000Source | -23,185,000Source | -70,398,000Source | -49,131,000Source | -5,435,000Source | -63,500,000Source | -44,318,000Source | -131,013,000Source | -116,210,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,000Source | — | 0Source | — | — | -8,000Source | — | — | -14,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 1,760,000Source | -13,774,000Source | — | 1,802,000Source | -16,363,000Source | — | 1,701,000Source | -4,309,000Source | -37,000Source | 641,000Source | 5,469,000Source | -17,212,000Source |
| Liabilities and EquityUSD | 12,413,000Source | 7,435,000Source | 25,814,000Source | 8,941,000Source | 10,708,000Source | 27,299,000Source | 6,731,000Source | 10,856,000Source | 6,951,000Source | 6,724,000Source | 11,965,000Source | 3,241,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,789,000Source | 13,514,000Source | 3,762,000Source | 3,561,000Source | 12,633,000Source | 6,340,000Source | 2,352,000Source | 14,059,000Source | 3,563,000Source | 2,366,000Source | 5,914,000Source | 10,078,000Source |
| Operating Lease, Liability, CurrentUSD | 163,000Source | 197,000Source | — | 177,000Source | 200,000Source | 168,000Source | 185,000Source | 207,000Source | 181,000Source | 192,000Source | — | — |
| Accounts Payable, CurrentUSD | 2,731,000Source | — | 1,858,000Source | 1,706,000Source | 1,203,000Source | 2,827,000Source | 1,188,000Source | 2,605,000Source | 1,931,000Source | 744,000Source | 1,413,000Source | 568,000Source |
| Operating Lease, Liability, NoncurrentUSD | 148,000Source | 312,000Source | 122,000Source | 185,000Source | 362,000Source | 159,000Source | 227,000Source | 413,000Source | 196,000Source | 268,000Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -166,000Source | -54,000Source | — | -156,000Source | -30,000Source | — | -142,000Source | — | 0Source | -133,000Source | -111,000Source | -103,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,144,000Source | 1,159,000Source | 1,359,000Source | 1,310,000Source | 320,000Source | 1,510,000Source | 979,000Source | 1,297,000Source | 1,207,000Source | 1,429,000Source | 529,000Source | 273,000Source |
| Long-term DebtUSD | — | 11,155,000Source | — | — | — | — | — | — | — | — | — | 18,124,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -4,595,000Source | 1,383,000Source | -6,356,000Source | -6,462,000Source | -6,898,000Source | -4,822,000Source | -19,215,000Source | -11,207,000Source | -14,811,000Source | -10,522,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 0Source | 0Source | 100,000Source | 194,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 956,000Source | — | 2,595,000Source | 648,000Source | 760,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 896,000Source | 441,000Source | 1,197,000Source | -1,661,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,568,000Source | -4,322,000Source | -17,955,000Source | -17,137,000Source | -7,800,000Source | -5,939,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -25,000Source | 0Source | -59,000Source | -22,000Source | -10,000,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 25,000Source | 0Source | 59,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 26,057,000Source | 4,917,000Source | 17,412,000Source | 13,212,000Source | 17,500,000Source | 6,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 21,470,000Source | 595,000Source | -616,000Source | -3,947,000Source | -300,000Source | 61,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 17,000Source | — | 27,000Source | 14,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 999,000Source | 1,096,000Source | 1,051,000Source | 890,000Source | 1,077,000Source | 956,000Source | 3,793,000Source | 2,595,000Source | 648,000Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 64,000Source | 0Source | 58,000Source | 345,000Source | 5,285,000Source | 3,137,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 100,000Source | 131,000Source | 132,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 73,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -91,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,741,000Source | 2,911,000Source | 2,968,000Source | 2,543,000Source | 3,081,000Source | 2,907,000Source | 10,997,000Source | 9,624,000Source | 9,328,000Source | 5,971,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -10,462,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -10,522,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 7,000Source | 0Source | 18,000Source | 0Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 6,000Source | 16,000Source | 203,000Source | 9,000Source | 189,000Source | 0Source | 213,000Source | 526,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,585,000Source | 1,410,000Source | -6,356,000Source | -6,448,000Source | -6,898,000Source | -4,813,000Source | -19,182,000Source | -11,141,000Source | -14,803,000Source | -10,462,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -10,000Source | -27,000Source | 0Source | -14,000Source | 0Source | -9,000Source | -33,000Source | -66,000Source | -8,000Source | -60,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,686,000Source | 1,410,000Source | -8,932,000Source | -6,565,000Source | -6,935,000Source | -4,813,000Source | -19,436,000Source | -11,141,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,797,000Source | 6,695,000Source | 428,000Source | -897,000Source | -611,000Source | 1,036,000Source | 4,825,000Source | 5,841,000Source | -4,924,000Source | -3,547,000Source |
| Operating ExpensesUSD | — | — | 6,392,000Source | 5,326,000Source | 6,784,000Source | 5,695,000Source | 6,280,000Source | 5,858,000Source | 24,152,000Source | 17,104,000Source | 10,062,000Source | 6,996,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 35,000Source | 42,000Source | 234,000Source | 68,000Source | 60,000Source | 47,000Source | 51,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 8,000Source | 1,000Source | 15,000Source | 12,000Source | 6,600,000Source | 7,300,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | 1,077,000Source | 956,000Source | 3,793,000Source | — | — | — |
| Depreciation | — | — | —Source | —Source | — | —Source | — | — | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 14,000Source | 0Source | 130,000Source | — | 0Source | 130,000Source | 56,000Source | 142,000Source | 34,000Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | —Source | —Source |
| Operating Income (Loss)USD | — | — | -6,392,000Source | -5,312,000Source | -6,784,000Source | -5,565,000Source | — | -5,858,000Source | -24,022,000Source | -17,048,000Source | -9,887,000Source | -6,975,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 35,000Source | 42,000Source | 234,000Source | 68,000Source | 60,000Source | 47,000Source | 51,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | -6,891,000Source | -4,822,000Source | -19,197,000Source | -11,141,000Source | 14,800,000Source | 10,500,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 7,000Source | 0Source | 18,000Source | 0Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -10,000Source | -27,000Source | 0Source | -14,000Source | 0Source | -9,000Source | -33,000Source | -66,000Source | -8,000Source | -60,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,585,000Source | 1,410,000Source | -6,356,000Source | -6,448,000Source | -6,898,000Source | -4,813,000Source | -19,182,000Source | -11,141,000Source | -14,803,000Source | -10,462,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.45Source | 0.16Source | -0.55Source | -0.66Source | -0.58Source | -0.49Source | -1.91Source | -1.51Source | -13.72Source | -0.28Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.45Source | 0.13Source | -0.55Source | -0.66Source | -0.58Source | -0.49Source | -1.91Source | -1.51Source | -13.72Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 10,339,000Source | 8,851,000Source | 16,385,000Source | 10,004,000Source | 12,047,000Source | 9,756,000Source | 10,190,000Source | 7,359,000Source | 1,079Source | 37,945,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,339,000Source | 10,751,000Source | 16,385,000Source | 10,004,000Source | 12,047,000Source | 9,756,000Source | 10,190,000Source | 7,359,000Source | 1,079Source | — |
| Interest Expense (non-operating)USD | — | — | 6,000Source | 16,000Source | 203,000Source | 9,000Source | 189,000Source | 0Source | 213,000Source | 526,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 100,000Source | 131,000Source | 132,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 18,000Source | 17,000Source | 73,000Source | 194,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 2,741,000Source | 2,911,000Source | 2,968,000Source | 2,543,000Source | 3,081,000Source | 2,907,000Source | 10,997,000Source | 9,624,000Source | 9,328,000Source | 5,971,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 102,000Source | 21,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -10,462,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,271,000Source | -11,141,000Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -10,522,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -0.28Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 4,900,000Source | 3,335,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,686,000Source | 1,410,000Source | -8,932,000Source | -6,565,000Source | -6,935,000Source | -4,813,000Source | -19,436,000Source | -11,141,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,797,000Source | 6,695,000Source | 428,000Source | -897,000Source | -611,000Source | 1,036,000Source | 4,825,000Source | 5,841,000Source | -4,924,000Source | -3,547,000Source |
| Operating ExpensesUSD | — | — | 6,392,000Source | 5,326,000Source | 6,784,000Source | 5,695,000Source | 6,280,000Source | 5,858,000Source | 24,152,000Source | 17,104,000Source | 10,062,000Source | 6,996,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 101,000Source | 0Source | — | 117,000Source | 37,000Source | 0Source | 254,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 3,651,000Source | 2,415,000Source | 3,816,000Source | 3,152,000Source | 3,199,000Source | 2,951,000Source | 13,155,000Source | 7,480,000Source | 734,000Source | 1,025,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | 27,000Source | — | — | — | 9,000Source | — | 66,000Source | — | — |
Offerings
Registration 333-298536
Registration 333-296166
Registration 333-293107
Filing attachments
ex107.htm · S-1 · 2026-08-24
Calculation of Filing Fee Tables S-1 Serina Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric…
Read attachment ↗ser-20260813xex991_earning.htm · 8-K · 2026-08-13
EX-99.1 2 ser-20260813xex991_earning.htm EX-99.1 Document Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - - Appointment of Farrell Simon, Pharm. D., to the Board of Directors - HUNTSVILLE, August 13, 2026 (GLOBE NEWSWIRE) - Serina Therapeutics, Inc…
Read attachment ↗ex107.htm · S-8 · 2026-08-13
Calculation of Filing Fee Tables S-8 Serina Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────────────────…
Read attachment ↗ex107.htm · S-3 · 2026-05-22
Calculation of Filing Fee Tables S-3 Serina Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric…
Read attachment ↗ser-20260514xex991_earning.htm · 8-K · 2026-05-14
EX-99.1 2 ser-20260514xex991_earning.htm EX-99.1 Document Exhibit 99.1 Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - - Closed $21.2 million private placement financing to support continued advancement of SER-252 - HUNTSVILLE, May 14, 2026 (GLOBE NEWSWIRE) - Serina Therapeutics, Inc…
Read attachment ↗ser-20260323xex991_earning.htm · 8-K · 2026-03-25
EX-99.1 2 ser-20260323xex991_earning.htm EX-99.1 Document Exhibit 99.1 Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) - Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pla…
Read attachment ↗